Regulatory Reference for Licensed Providers

503A vs 503B Compounding

The key difference: 503A pharmacies prepare patient-specific medications based on individual prescriptions. 503B outsourcing facilities produce medications in bulk under cGMP standards — no per-patient prescription required for eligible products. After FDA shortage-list changes, bulk copies of commercially available semaglutide or tirzepatide are generally restricted unless a separate lawful basis exists.

Important 2026 qualifier: "No per-patient prescription" describes how 503B facilities are allowed to produce eligible products. It is not permission to produce bulk copies of commercially available semaglutide or tirzepatide after those drugs left the FDA shortage list, unless a separate lawful basis exists.

Get Connected View catalogue

2026 update: After FDA removed semaglutide and tirzepatide from the drug shortage list, 503B bulk copies of those commercially available products are restricted. 503A patient-specific compounding may still be available when the preparation is not essentially a copy of an FDA-approved product and a valid prescription exists. RUO peptides are a third, separate category. This page is the canonical 2026 comparison: 503A vs 503B vs RUO.

503A

Traditional Compounding Pharmacy

State-licensed pharmacies that prepare patient-specific medications based on individual prescriptions. Each preparation is customized for a specific patient's documented medical need.

Patient-specific prescriptions required

State pharmacy license

USP <797>/<800> standards

Customizable formulations

Per-prescription pricing

503B

FDA-Registered Outsourcing Facility

FDA-registered facilities that produce medications in bulk under full cGMP standards. No per-patient prescription required for eligible products. Note: after FDA shortage-list changes, bulk copies of commercially available semaglutide or tirzepatide are generally restricted unless a separate lawful basis exists. Ideal for higher-volume clinics and licensed pharmacies seeking consistent wholesale supply on eligible items.

No per-patient prescription required for eligible products

FDA registration required

Full cGMP standards

Bulk/wholesale pricing

Consistent large-volume supply

Side-by-Side Comparison

Aspect

503A

503B

Regulatory basis

Section 503A of the FD&C Act

Section 503B of the FD&C Act

FDA registration

State-licensed pharmacy; not FDA-registered as outsourcing facility

Must register with FDA as an outsourcing facility

Per-patient prescription

Required — each preparation is patient-specific

Not required — bulk production without individual Rx

Production scale

Patient-specific, typically lower volume

Bulk production, higher volume

cGMP standards

USP <797>/<800> standards apply

Full FDA cGMP standards required

Who can order

Licensed prescribers with valid patient Rx

Licensed providers and pharmacies (wholesale)

Pricing model

Per-prescription pricing

Wholesale/bulk pricing

Documentation

CoA, BUD, patient prescription

CoA, BUD, FDA facility registration, cGMP certification

Same Platform

USA-Made cGMP RUO Peptides — Available on the Same Platform

Beyond 503A and 503B compounded GLPs, MedClinic Partners provides access to USA-manufactured cGMP research-use-only peptides on the same platform. One portal. One account contact. One cold-chain logistics network.

Learn about cGMP RUO Peptides

Common Questions

See the full FAQ for more.

What is the difference between 503A and 503B compounding?

503A refers to traditional compounding pharmacies that prepare patient-specific medications based on individual prescriptions. 503B refers to FDA-registered outsourcing facilities that produce medications in bulk under cGMP standards without requiring a per-patient prescription.

Can a 503A pharmacy source 503B products?

Yes. Licensed 503A compounding pharmacies are permitted to purchase bulk drug substances from FDA-registered 503B outsourcing facilities. MedClinic Partners facilitates this access through a separate credentialing process for licensed pharmacies.

Which channel is right for my clinic?

Clinics with established prescribing workflows and moderate volume often start with 503A. Higher-volume clinics seeking consistent bulk supply and wholesale pricing typically benefit from 503B access. MedClinic Partners provides access to both channels.

Access Both 503A and 503B Channels

MedClinic Partners provides licensed clinics and pharmacies with access to both compounding channels through a single NPI-verified portal.

Get Connected 503B Supply for Pharmacies